Related Experiment Video

Updated: Aug 16, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy

Jean-François Haince1, Michèle Rouleau, Michael J Hendzel

  • 1Health and Environment Unit, Laval University Hospital Research Center, CHUQ, Faculty of Medicine, Laval University, Québec, Canada.

Trends in Molecular Medicine
|September 13, 2005
PubMed

Insights

Transiently inhibiting DNA repair with poly(ADP-ribose) polymerase (PARP) inhibitors shows promise for cancer treatment, especially in BRCA-deficient tumors. Further research into poly(ADP-ribose) metabolism is needed for clinical application.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • DNA repair mechanisms are crucial for maintaining genomic stability.
  • Poly(ADP-ribose) polymerase (PARP) enzymes play a key role in DNA damage detection and signaling.
  • PARP inhibitors are emerging as a therapeutic strategy in oncology.

Purpose of the Study:

  • To explore the potential of transiently inhibiting DNA repair pathways using PARP inhibitors.
  • To investigate the selective killing of cancer cells with defective BRCA proteins through poly(ADP-ribose) synthesis inhibition.
  • To elucidate the molecular mechanisms underlying poly(ADP-ribose) metabolism in DNA repair.

Main Methods:

  • Utilizing potent poly(ADP-ribose) polymerase (PARP) inhibitors.
  • Analyzing DNA damage detection and repair processes.
  • Investigating poly(ADP-ribose) synthesis pathways.

Main Results:

  • Transient inhibition of DNA repair can enhance the efficacy of cancer treatments.
  • Inhibition of poly(ADP-ribose) synthesis shows potential for selectively targeting BRCA-deficient tumors.
  • Current research sheds light on PARP-mediated DNA damage signaling.

Conclusions:

  • PARP inhibitors offer a promising avenue for improving cancer therapy.
  • Targeting poly(ADP-ribose) metabolism may lead to selective cancer cell death in specific genetic contexts.
  • Further understanding of the molecular mechanisms is required for clinical translation.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...